C Pertusa

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

J.M. Fernández Gómez, Rosário Madero, Eduardo Solsona et al. · The Journal of Urology · 2009 · 655 citations · Full text

Medicine, Oncology, Urology +9

Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

J.M. Fernández Gómez, Eduardo Solsona, Miguel Unda et al. · European Urology · 2007 · 257 citations · Full text

Medicine, Oncology, Urology +6

Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

J.A. Martínez‐Pin ̃eiro, N Flores, Santiago Isorna et al. · British Journal of Urology · 2002 · 217 citations · Full text

Medicine, Oncology, Urology +7

HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

J A Martínez-Piñeiro, Luis Martínez‐Piñeiro, Eduardo Solsona et al. · The Journal of Urology · 2005 · 198 citations

Medicine, Oncology, Urology +10

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

J.M. Fernández Gómez, Rosário Madero, Eduardo Solsona et al. · European Urology · 2011 · 166 citations · Full text

Medicine, Oncology, Urology +8